Letter to the Editor
Lysostaphin and clarithromycin: a promising combination for the eradication of Staphylococcus aureus biofilms

https://doi.org/10.1016/j.ijantimicag.2011.02.009Get rights and content

References (5)

There are more references available in the full text version of this article.

Cited by (22)

  • Prediction of qualitative antibiofilm activity of antibiotics using supervised machine learning techniques

    2022, Computers in Biology and Medicine
    Citation Excerpt :

    Around 700 research articles, published between 1999 and 2021, were found in the literature search. Among these articles, 39 [5,38–75] fulfilled the inclusion criteria from which 663 observations were collected. From the collected data, 580 observations were used in the development of models.

  • Antibiofilm enzymes as an emerging technology for food quality and safety

    2018, Enzymes in Food Biotechnology: Production, Applications, and Future Prospects
  • Potential use of targeted enzymatic agents in the treatment of Staphylococcus aureus biofilm-related infections

    2017, Journal of Hospital Infection
    Citation Excerpt :

    To varying extents, all antibiotic/dispersal agent combinations examined in this study were more effective than enzymatic or antibiotic treatment alone. Previous research examining antibiotic/dispersin B and antibiotic/lysostaphin combinations vs antibiotics alone were consistent with the study findings.24,25 In conclusion, use of enzymatic agents in combination with existing antibiotics has the potential to improve the outcome for patients with S. aureus biofilm-associated infections such as soft tissue, implant and intravascular catheter infections, and should therefore be further explored as a viable novel treatment option for these difficult-to-treat infections.

  • Thermally triggered release of the bacteriophage endolysin CHAP<inf>K</inf> and the bacteriocin lysostaphin for the control of methicillin resistant Staphylococcus aureus (MRSA)

    2017, Journal of Controlled Release
    Citation Excerpt :

    Consisting of a single lytic domain (glycyl-glycine M23 endopeptidase), lysostaphin demonstrates potent antistaphylococcal activity through cleavage of the pentaglycine cross-bridges within the peptidoglycan of the bacterial cell wall. Active against a multitude of antibiotic susceptible, intermediate and resistant strains of bacteria, lysostaphin exhibits synergistic behaviour with multitude of antibiotics, phage lysins and antimicrobial peptides [18–20]. Successful application of lysostaphin has been demonstrated in cases of ocular infection, osteitis and endocarditis [21–23].

  • Cell wall hydrolases and antibiotics: Exploiting synergy to create efficacious new antimicrobial treatments

    2016, Current Opinion in Microbiology
    Citation Excerpt :

    Subsequently, combinations of lysostaphin with antibiotics were demonstrated to be more effective in the treatment of biofilm-based infections than either of the agents alone [34,35]. A pairing of nine different antibiotics with lysostaphin demonstrated that many combinations were effective in eradicating S. aureus biofilms in vitro, although strain dependencies were noted [36•]. A lysostaphin–nisin combination was effective against pre-formed biofilm of bovine mastitis-derived staphylococci [37].

  • Are antibiotics and surgery sufficient to treat biofilm-associated infections?

    2013, Enfermedades Infecciosas y Microbiologia Clinica
View all citing articles on Scopus
View full text